Adenocarcinoma of the Lung
📧 Sign up to get email alerts when something new happens for Adenocarcinoma of the Lung.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-02-27Clinical Trial Update: Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer [Phase 2, Phase 3]
A phase 2/3 trial evaluated adding bevacizumab to standard chemotherapy for advanced, metastatic, or recurrent non-small cell lung cancer; t…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating erlotinib with radiation therapy and chemotherapy for inoperable Stage III non-small cell lung cancer was terminate…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery [Phase 3]
A Phase 3 trial evaluating whether adding AE-941 to combination chemotherapy and radiation improves outcomes for patients with stage III non…
-
CLINICAL_TRIALS trial_result · 2012-03-26Clinical Trial Update: Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) [Phase 2]
Phase II trial comparing maintenance temozolomide versus observation in stable or responding stage III/IV Non-Small Cell Lung Cancer. The st…
-
CLINICAL_TRIALS trial_result · 2011-02-17Clinical Trial Update: VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features [Phase 2]
Phase 2 trial of Velcade (bortezomib) in previously treated stage IIIB/IV bronchioloalveolar carcinoma and BAC-featured adenocarcinoma of th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.